Chinese Science Bulletin

, Volume 57, Issue 6, pp 631–638 | Cite as

Correlation between platelet gelsolin levels and different types of coronary heart disease

  • Yue Liu
  • HuiJun Yin
  • YueRong Jiang
  • Mei Xue
  • KeJi Chen
Open Access
Article Preclinical Medicine

Abstract

Gelsolin is an important cytoskeletal protein of platelets and studies have shown a close relationship between gelsolin and cardiovascular disease. However, the role of gelsolin in the development of coronary heart disease (CHD) is unclear. In this study, we record the distribution of gelsolin in human platelets and plasma and its association with different types of CHD. This study included 114 cases, with 33 stable angina pectoris (SAP) cases, 81 acute coronary syndrome (ACS) cases—composed of 39 unstable angina pectoris (UAP) and 42 acute myocardial infarction (AMI) cases, and 31 healthy control participants. Gelsolin concentration in platelet rich plasma (PRP) and platelet poor plasma (PPP), actin filament (F-actin) and Gc-globulin of PPP were determined by enzyme-linked immunoadsorbent assay (ELISA). The fluorescence intensity of CD62p and cytoplasmic calcium ([Ca2+]i) in human platelets measured by flow cytometry. We also used turbidimetry to detect the platelet aggregation rate (PAR). We analyzed the correlation between platelet gelsolin concentration and CD62p or plasma F-actin levels among each different patient group. Compared with the control group, the gelsolin level in PRP of UAP and AMI groups increased significantly (P<0.01), while the gelsolin level in PPP of all the three patient groups decreased markedly (P<0.01), and the CD62p, PAR, [Ca2+]i of platelets, F-actin and Gc-globulin of the UAP and AMI groups increased significantly (P<0.01). Compared with the SAP group, the gelsolin level in PRP, the PAR, [Ca2+]i of platelets and CD62p of other two groups increased significantly (P<0.01), F-actin of the AMI group increased markedly (P<0.01). Platelet cytoskeleton protein dynamics vary among the different types of CHD. Platelet gelsolin levels are markedly increased and accompanied by increased platelet activity, F-actin and [Ca2+]i of ACS patients, while gelsolin levels in PPP are markedly lower. Abnormally increased platelet gelsolin levels show high positive correlation with the level of platelet activity. Therefore, platelet gelsolin might be a novel molecular marker and/or a new potential therapeutic target of anti-platelet therapy of ACS.

Keywords

gelsolin F-actin coronary heart disease platelet activation acute coronary syndromes 

References

  1. 1.
    Gergely F, Andrea F, Gabriella P, et al. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol, 2010, 2: 171–186CrossRefGoogle Scholar
  2. 2.
    Li X F, Jiang Y R, Wu C F, et al. Study on the correlation between platelet function proteins and symptom complex in coronary heart disease (in Chinese). Mol Cardiol China, 2009, 9: 326–331Google Scholar
  3. 3.
    Gibbons R J, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: A report of the American college of cardiology/American Heart Association task force on practice guidelines (committee on management of patients with chronic stable angina). J Am Coll Cardio, 1999, 33: 2092–2197CrossRefGoogle Scholar
  4. 4.
    Braunwald E, Antman E M, Kupersmith J W, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocaridal infarction-summary article: A report of the American college of cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). J Am Coll Cardio, 2002, 40: 1266–1374CrossRefGoogle Scholar
  5. 5.
    World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA, 1997, 277: 925–926CrossRefGoogle Scholar
  6. 6.
    Zhuang M M, Wen Y X, Liu S L, et al. Determination of the level of cytopplasmic free calcium in human platelets with flow cytometry (in Chinese). J Xi’an Jiaotong Univ (Med Sci), 2005, 26: 508–510Google Scholar
  7. 7.
    Grynkiewicz G, Poenie M, Tsien R Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem, 1985, 260: 3440–3450Google Scholar
  8. 8.
    Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr, 2006, 83: 456S–460SGoogle Scholar
  9. 9.
    Brydon L, Magid K, Steptoe A. Platelets, coronary heart disease, and stress. Brain Behav Immun, 2006, 20: 113–119CrossRefGoogle Scholar
  10. 10.
    Hsu-Lin S, Berman C L, Furie B C, et al. A platelet membrane protein expressed during platelet activation and secretion: Studies using a monoclonal antibody specific for thrombin-activated platelets. J Biol Chem, 1984, 259: 9121–9126Google Scholar
  11. 11.
    Michelson A D, Furman M I. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol, 1999, 6: 342–348CrossRefGoogle Scholar
  12. 12.
    Furman M I, Benoit S E, Barnard M R, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol, 1998, 31: 352–358CrossRefGoogle Scholar
  13. 13.
    Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation, 1995, 92: 1693–1696Google Scholar
  14. 14.
    Shimomura H, Ogawa H, Arai H, et al. Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction. Am J Cardiol, 1998, 81: 397–400CrossRefGoogle Scholar
  15. 15.
    Lichtman J H, Bigger J T Jr, Blumenthal J A, et al. Depression and coronary heart disease. Recommendations for screening, referral, and treatment: A science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research. Endorsed by the American Psychiatric Association. Circulation, 2008, 118: 1768–1775CrossRefGoogle Scholar
  16. 16.
    García A. Clinical proteomics in platelet research: Challenges ahead. J Thromb Haemost, 2010, 8: 1784–1785CrossRefGoogle Scholar
  17. 17.
    Kwiatkowski D J, Stossel T P, Orkin S H, et al. Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature, 1986, 323: 455–458CrossRefGoogle Scholar
  18. 18.
    Allen, P G. Actin filament uncapping localizes to ruffling lamellae and rocketing vesicles. Nat Cell Biol, 2003, 5: 972–979CrossRefGoogle Scholar
  19. 19.
    Liu Y, Jiang Y R, Yin H J, et al. Gelsolin and cardiovascular diseases (in Chinese). Mol Cardiol China, 2011, 11: 50–53Google Scholar
  20. 20.
    Vasconcellos C A, Lind S E. Coordinated inhibition of actin-induced platelet aggregation by plasma gelsolin and vitamin D-binding protein. Blood, 1993, 82: 3648–3657Google Scholar
  21. 21.
    Haddad J G, Harper K D, Guoth M, et al. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci USA, 1990, 87: 1381–1385CrossRefGoogle Scholar
  22. 22.
    Lee W M, Galbraith R M. The extracellular actin-scavenger system and actin toxicity. N Engl J Med, 1992, 326: 1335–1341CrossRefGoogle Scholar
  23. 23.
    Suhler E, Lin W, Yin H L. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock and myonecrosis. Crit Care Med, 1997, 25: 594–598CrossRefGoogle Scholar
  24. 24.
    White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metabol, 2000, 11: 320–327CrossRefGoogle Scholar
  25. 25.
    López-Farré A J, Mateos-Cáceres P J, Sacristán D, et al. Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: A proteomic study. J Proteome Res, 2007, 6: 2481–2487CrossRefGoogle Scholar
  26. 26.
    Kato M, Kambe M, Kajiyama G. Increased cytosolic free Mg2+ and Ca2+ in platelets of patients with vasospastic. Am J Physiol, 1998, 274: 548–554Google Scholar
  27. 27.
    Fujinishi A, Takahara K, Ohba C, et al. Effects of nisoldipine on cytosolic calcium, platelet aggregation, and coagulation/fibrinolysis in patients with coronary artery disease. Angiology, 1997, 48: 515–521CrossRefGoogle Scholar
  28. 28.
    Li G H, Shi Y, Chen Y, et al. Gelsolin regulates cardiac remodeling after myocardial infarction through DNase I-mediated apoptosis. Circ Res, 2009, 104: 896–904CrossRefGoogle Scholar

Copyright information

© The Author(s) 2011

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  • Yue Liu
    • 1
  • HuiJun Yin
    • 1
  • YueRong Jiang
    • 1
  • Mei Xue
    • 1
  • KeJi Chen
    • 1
  1. 1.Department of Cardiovascular Disease, Xiyuan HospitalChina Academy of Chinese Medical SciencesBeijingChina

Personalised recommendations